NCT07249957Not yet recruiting
Reducing Radiation Target Volume for Stage IIb Cervical Cancer
Reducing Radiation Target Volume in Radical Radiotherapy for Stage IIb Cervical Cancer: A Single-arm Exploratory Study
Source: ClinicalTrials.gov · Last updated 25 Nov 2025
Brief summary (registry, in English)
This is a domestic single-center prospective clinical trial. The study selected patients with histologically confirmed cervical squamous cell carcinoma, diagnosed as stage IIb according to the FIGO 2018 staging principle (tumor size \< 4 cm). The patients first received 6 cycles of induction chemotherapy (carboplatin (AUC2) + paclitaxel (80 mg/m2), q1w), followed by concurrent chemoradiotherapy with a platinum-based regimen. The external beam radiation field only covered the entire uterus (including the primary lesion of the cervix), the bilateral parametrium, and the lesion of the cervix/vagina extending 3 cm downward. A total of 60 participants are planned to be included in the study.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 18 Sept 2025
- Start date
- Nov 2025
- Primary completion date
- Oct 2027
- Lead sponsor
- Chongqing University Cancer Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT07249957
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Nov 2025 to the primary completion date, Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received radiotherapy for pelvic malignant tumors in the past;
- Patients who have received partial hysterectomy or radical hysterectomy in the past;
Other illness
- Active or uncontrolled severe infections;
- Cirrhosis, decompensated liver disease;
- History of immunodeficiency, including HIV positive or having other acquired congenital immune deficiency diseases;
- Chronic renal insufficiency and renal failure;
- Patients with other malignancies that require treatment and/or newly diagnosed within 5 years;
- Myocardial infarction, severe arrhythmia, and ≥ grade 2 congestive heart failure (NYHA classification);
- Patients with a history of severe allergic reaction to platinum-based chemotherapy drugs;
- Comorbidities, requiring the use of drugs that cause significant liver and kidney damage during treatment, such as tuberculosis, etc.;
- Patients with serious accompanying diseases or other special conditions that seriously endanger their safety or affect their ability to complete the study.
Other
- Patients who have undergone pelvic artery embolization;
- Patients who cannot understand the experimental content and cannot cooperate, or who refuse to sign the informed consent form;
Who the study is looking for
- The patient voluntarily participated in this study and signed the informed consent form;
- Age range: 50 to 75 years old;
- Patients with cervical cancer who had not undergone surgery or chemotherapy and were initially diagnosed with squamous cell carcinoma by pathological histology, and were HPV high-risk positive;
- According to the 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system, it was stage IIb (tumor size \< 4 cm);
- ECOG score: 0 to 1, with an expected survival of more than 6 months;
- Pregnant women must undergo a pregnancy test (serum or urine) 7 days before enrollment, and the result must be negative, and they are willing to use appropriate contraceptive methods during the trial;
- According to the investigator's judgment, there are no absolute contraindications to radiotherapy and chemotherapy or surgery, and they can comply with the trial protocol.
Age in the registry: 50 years to 75 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.